Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 86

1.

Clinical pharmacokinetics of carboplatin.

Oguri S, Sakakibara T, Mase H, Shimizu T, Ishikawa K, Kimura K, Smyth RD.

J Clin Pharmacol. 1988 Mar;28(3):208-15.

PMID:
3283185
2.

A radioimmunoassay procedure for tallysomycin S10b in human plasma and urine.

Gaver RC, Dixon CW, Smyth RD.

Cancer Chemother Pharmacol. 1986;16(3):207-10.

PMID:
2421934
3.

Genetic investigation of a negatively phototactic strain of Chlamydomonas reinhardtii.

Smyth RD, Ebersold WT.

Genet Res. 1985 Oct;46(2):133-48. No abstract available.

PMID:
4085795
4.

Determination of tiodazosin concentrations in human plasma with a fluorescence high-performance liquid chromatographic method.

Forgue ST, Van Harken DR, Smyth RD.

J Chromatogr. 1985 Jul 12;342(1):221-7. No abstract available.

PMID:
4044753
5.

Bioavailability and pharmacokinetics of etoposide (VP-16).

Smyth RD, Pfeffer M, Scalzo A, Comis RL.

Semin Oncol. 1985 Mar;12(1 Suppl 2):48-51.

PMID:
3975657
6.

Bioequivalence evaluation of new megestrol acetate formulations in humans.

Gaver RC, Pittman KA, Reilly CM, Smyth RD, Goodson PJ, Fenzl E, Breault GO.

Semin Oncol. 1985 Mar;12(1 Suppl 1):17-9.

PMID:
3975646
7.

Clinical pharmacology of intraperitoneal cisplatin.

Lopez JA, Krikorian JG, Reich SD, Smyth RD, Lee FH, Issell BF.

Gynecol Oncol. 1985 Jan;20(1):1-9.

PMID:
4038390
8.

Pharmacokinetics of mitomycin C in dogs: application of a high-performance liquid chromatographic assay.

Barbhaiya RH, Papp EA, Van Harken DR, Smyth RD.

J Pharm Sci. 1984 Sep;73(9):1220-3.

PMID:
6436466
9.

Evaluation of the bioavailability of sarpicillin, the methoxymethyl ester of hetacillin, in humans.

Stavchansky S, Pearlman RS, Van Harken DR, Smyth RD, Hottendorf GH, Martin A, Newburger J, Schneider LW.

J Pharm Sci. 1984 Feb;73(2):169-73.

PMID:
6707877
10.

Bleomycin disposition in children with cancer.

Yee GC, Crom WR, Lee FH, Smyth RD, Evans WE.

Clin Pharmacol Ther. 1983 May;33(5):668-73.

PMID:
6188571
11.

Disposition of orally administered 14C-prednimustine in cancer patients.

Gaver RC, Deeb G, Pittman KA, Issell BF, Mittelman A, Smyth RD.

Cancer Chemother Pharmacol. 1983;11(3):139-43.

PMID:
6640823
12.

Pharmacokinetics of intramuscular ceforanide in infants, children, and adolescents.

Dajani AS, Thirumoorthi MC, Bawdon RE, Buckley JA, Pfeffer M, Van Harken DR, Smyth RD.

Antimicrob Agents Chemother. 1982 Feb;21(2):282-7.

13.

Change in flagellar beat frequency of Chlamydomonas in response to light.

Smyth RD, Berg HC.

Prog Clin Biol Res. 1982;80:211-5. No abstract available.

PMID:
7100179
14.

Ceforanide kinetics in renal insufficiency.

Hawkins SS, Alford RH, Stone WJ, Smyth RD, Pfeffer M.

Clin Pharmacol Ther. 1981 Oct;30(4):468-74.

PMID:
7285481
15.

Human pharmacokinetics and disposition of sarmoxicillin, a lipophilic amoxicillin prodrug.

Smyth RD, Pfeffer M, Van Harken DR, Cohen A, Hottendorf GH.

Antimicrob Agents Chemother. 1981 Jun;19(6):1004-12.

16.

Comparative tissue distribution of ceforanide, cefazolin, and cefamandole in rats.

Lee FH, Smyth RD, Van Harken DR.

Antimicrob Agents Chemother. 1981 Apr;19(4):625-7.

17.

Disposition of anagrelide, an inhibitor of platelet aggregation.

Gaver RC, Deeb G, Pittman KA, Smyth RD.

Clin Pharmacol Ther. 1981 Mar;29(3):381-6.

PMID:
7471608
18.

Preliminary studies of the pharmacokinetics of talisomycin in the rhesus monkey.

Van Harken DR, Smyth RD, Lee FH, Strong JE, Hottendorf GH.

Res Commun Chem Pathol Pharmacol. 1981 Mar;31(3):403-17.

PMID:
6166971
19.

Human perinatal distribution of butorphanol.

Pittman KA, Smyth RD, Losada M, Zighelboim I, Maduska AL, Sunshine A.

Am J Obstet Gynecol. 1980 Dec 1;138(7 Pt 1):797-800.

PMID:
7446613
20.

Light Antennas in phototactic algae.

Foster KW, Smyth RD.

Microbiol Rev. 1980 Dec;44(4):572-630. Review. No abstract available.

21.

Bioavailability and metabolism of potassium phosphanilate in laboratory animals and humans.

Lee FH, Van Harken DR, Vasiljev M, Smyth RD, Hottendorf GH.

Antimicrob Agents Chemother. 1980 Nov;18(5):746-52.

22.

Placental transfer and other physiologic studies with intravenous butorphanol in the anesthetized pregnant ewe.

Maduska AL, Pittman KA, Ahokas RA, Anderson GD, Lipshitz J, Morrison JC, Smyth RD.

Res Commun Chem Pathol Pharmacol. 1980 Aug;29(2):229-41.

PMID:
7414046
23.

Pharmacokinetics of subcutaneous and intramuscular butorphanol in dogs.

Pfeffer M, Smyth RD, Pittman KA, Nardella PA.

J Pharm Sci. 1980 Jul;69(7):801-3.

PMID:
7391944
24.

Disposition of parenteral butorphanol in man.

Gaver RC, Vasiljev M, Wong H, Monkovic I, Swigor JE, Van Harken DR, Smyth RD.

Drug Metab Dispos. 1980 Jul-Aug;8(4):230-5.

PMID:
6105056
25.

Application of pharmacokinetics and biopharmaceutics in the design of toxicological studies.

Smyth RD, Hottendorf GH.

Toxicol Appl Pharmacol. 1980 Apr;53(2):179-95. No abstract available.

PMID:
7394763
26.

Comparative pharmacokinetics of ceforanide (BL-S786R) and cefazolin in laboratory animals and humans.

Lee FH, Pfeffer M, Van Harken DR, Smyth RD, Hottendorf GH.

Antimicrob Agents Chemother. 1980 Feb;17(2):188-92.

27.

Serum levels of butorphanol by radioimmunoassay.

Pittman KA, Smyth RD, Mayol RF.

J Pharm Sci. 1980 Feb;69(2):160-3.

PMID:
7359315
28.
29.

Biological disposition of 8-methoxsalen in rat and man.

Smyth RD, Van Harken DR, Pfeffer M, Nardella PA, Vasiljev M, Pinto JS, Hottendorf GH.

Arzneimittelforschung. 1980;30(10):1725-30. No abstract available.

PMID:
7192111
30.

Clinical pharmacokinetics and safety of high doses of ceforanide (BL-S786R) and cefazolin.

Smyth RD, Pfeffer M, Glick A, Van Harken DR, Hottendorf GH.

Antimicrob Agents Chemother. 1979 Nov;16(5):615-21.

31.

Evaluation of the availability of drugs incorporated in rat laboratory diet.

Smyth RD, Gaver RC, Dandekar KA, Van Harken DR, Hottendorf GH.

Toxicol Appl Pharmacol. 1979 Sep 30;50(3):493-9. No abstract available.

PMID:
516062
32.

Physiological disposition and subcellular localization of 14C-fenclorac in the rat.

Mathur PP, Smyth RD.

Res Commun Chem Pathol Pharmacol. 1979 Jul;25(1):23-31.

PMID:
451357
33.

GLC assay of fenclorac in human plasma.

DeLong AF, Polk A, Martin G, Smyth RD, Reavey-Cantwell NH.

J Pharm Sci. 1978 Aug;67(8):1171-3.

PMID:
307596
34.

Sex-related differences in the impairment of hepatic drug-metabolizing enzymes in rats with adjuvant disease.

Mathur PP, Carr GS, Smyth RD.

Biochem Pharmacol. 1978 May 1;27(9):1379-80. No abstract available.

PMID:
697939
35.

Effects of a nonsteroidal anti-inflammatory agent and phenobarbital on hepatic microsomal mono-oxygenases in adjuvant disease in the rat.

Mathur PP, Smyth RD, Witmer CM, Carr GS.

Biochem Pharmacol. 1978;27(13):1771-4. No abstract available.

PMID:
708458
36.

Effect of antacids on aspirin dissolution and bioavailability.

Nayak RK, Smyth RD, Polk A, Herczeg T, Carter V, Visalli AJ, Reavey-Cantwell NH.

J Pharmacokinet Biopharm. 1977 Dec;5(6):597-613. No abstract available.

PMID:
599409
37.

Temporal pattern and reversal of impaired hepatic mono-oxygenases by phenobarbital in rats with developing and established adjuvant disease.

Mathur PP, Smyth RD, Witmer CM, Carr GS, Reavey-Cantwell NH.

J Pharmacol Exp Ther. 1977 Oct;203(1):169-83. No abstract available.

PMID:
909051
38.
39.

Quantitative determination of fenclorac in serum.

Lee JK, Smyth RD, Polk A, Herczeg T, Tsuei CT, Reavey-Cantwell NH.

J Pharm Sci. 1977 Jun;66(6):832-4.

PMID:
301563
40.

Studies on the in vitro inhibition of prostaglandin synthetase by fenclorac (alpha, m-dichloro-p-cyclohexylphenylacetic acid) and indomethacin.

Procaccini RL, Smyth RD, Reavey-Cantwell NH.

Biochem Pharmacol. 1977 Jun 1;26(11):1051-7. No abstract available.

PMID:
18151
41.

Comparative metabolism of fenclorac in rat, dog, monkey, and man.

DeLong AF, Smyth RD, Polk A, Nayak RK, Martin G, Douglas GH, Reavey-Cantiwell NH.

Drug Metab Dispos. 1977 Mar-Apr;5(2):122-31.

PMID:
15804
42.

Comparative effects of fenclorac and indomethacin on gastrointestinal blood loss in the rat.

Smyth RD, Mathur PP, Procaccini RL, Carr GS, Reavey-Cantwell NH.

Toxicol Appl Pharmacol. 1976 Dec;38(3):507-15. No abstract available.

PMID:
1087763
43.

The antiphlogistic, antinociceptive and antipyretic properties of fenclorac.

Nuss GW, Smyth RD, Breder CH, Hitchings MJ, Mir GN, Reavey-Cantwell NH.

Agents Actions. 1976 Nov;6(6):735-47.

PMID:
1008019
44.

Blood levels in methaqualone in man following chronic therapeutic doses.

Delong AF, Smyth RD, Polk A, Nayak RK, Reavey-Cantwell NH.

Arch Int Pharmacodyn Ther. 1976 Aug;222(2):322-31.

PMID:
984982
45.

Correlation of in vitro and in vivo methodology for evaluation of antacids.

Smyth RD, Herczeg T, Wheatley TA, Hause W, Reavey-Cantwell NH.

J Pharm Sci. 1976 Jul;65(7):1045-7.

PMID:
8626
46.

Correlation between dissolution characteristics and absorption of methaqualone from solid dosage forms.

Chemburkar PB, Smyth RD, Buehler JD, Shah PB, Joslin RS, Polk A, Reavey-Cantwell NH.

J Pharm Sci. 1976 Apr;65(4):529-33.

PMID:
1271252
47.

Comparative effect of phenobarbital and methaqualone on warfarin metabolism in the rat.

Procaccini RL, Mathur PP, Smyth RD, Reavey-Cantwell NH.

Biochem Pharmacol. 1976 Feb 15;25(4):379-82. No abstract available.

PMID:
938570
48.

Induction of hepatic enzymes by methaqualone and effect on warfarin-induced hypoprothrombinemia.

Mathur PP, Smyth RD, Herczeg T, Reavey-Cantwell NH.

J Pharmacol Exp Ther. 1976 Jan;196(1):204-12.

PMID:
1246011
49.

Linkage of six genes in Chlamydomonas reinhardtii and the construction of linkage test strains.

Smyth RD, Martinek GW, Ebersold WT.

J Bacteriol. 1975 Dec;124(3):1615-7.

50.

Age differences affecting induction of hepatic drug metabolizing enzymes by methaqualone and phenobarbital in the rat.

Mathur PP, Boren JA, Smyth RD, Reavey-Cantwell NH.

Res Commun Chem Pathol Pharmacol. 1975 May;11(1):39-44.

PMID:
1153862

Supplemental Content

Loading ...
Support Center